Pulmonary arterial hypertension therapy business Morphogen-IX has been backed by Cambridge Enterprise and Cambridge Innovation Capital in a $23.3m round.

Morphogen-IX, a UK-based developer of pulmonary arterial hypertension treatments based on University of Cambridge research, closed an £18.4m ($23.3m) series B round featuring the Cambridge Enterprise tech transfer office (TTO) yesterday.
Cambridge Innovation Capital, the patient capital fund founded by University of Cambridge, also took part in the round, which was led by life sciences-focused investment firm Medicxi.
Cambridge Enterprise Seed Funds was mentioned in the announcement, but it was unclear whether Cambridge Enterprise had invested through the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?